Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07710417

FLOAT for Healthcare PTSS

This early-stage pilot trial aims to examine the feasibility, tolerability, and safety of Floatation-REST, or Reduced Environmental Stimulation Therapy via floatation in frontline healthcare workers, first responders, and emergency medical personnel who experience post-traumatic stress symptoms.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–64 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Early Phase 1

Primary location

Laureate Institute for Brain Research

Tulsa, Oklahoma, 74136, United States

Location status: Recruiting

Location contact

LIBR Assessment Team

CONTACT

[email protected]

918-502-5100

About this study

Frontline healthcare workers, first responders, and emergency medical personnel are repeatedly exposed to occupational stressors and potentially traumatic events, placing them at elevated risk for post-traumatic stress symptoms (PTSS), burnout, anxiety, and related impairments. Current stress-reduction approaches for healthcare workers often have limited evidence for efficacy or may be difficult to implement in high-demand emergency and healthcare settings. Therefore, rapid, low-burden interventions that are feasible, tolerable, and safe for this population are needed.

Floatation-REST, or Reduced Environmental Stimulation Therapy, is a non-pharmacological intervention that reduces sensory input to the nervous system through the act of floating supine in a pool of warm water saturated with Epsom salt. The float environment is designed to reduce visual, auditory, thermal, tactile, vestibular, and proprioceptive stimulation. Prior studies suggest that Floatation-REST may acutely reduce stress and anxiety-related symptoms, but it has not yet been systematically evaluated in frontline healthcare workers with elevated PTSS.

This single-site, double-arm pilot study will examine the feasibility, tolerability, and safety of two 60-minute sessions of Floatation-REST compared with a documentary-viewing condition in adults ages 18 to 64 with work-related post-traumatic stress symptoms. Up to 30 participants will be recruited, with the goal of retaining 15 completers randomized on a 2:1 basis to Floatation-REST versus comparator condition. Participants will complete two in-person study visits at the Laureate Institute for Brain Research, including self-report questionnaires, blood and saliva collection, functional magnetic resonance imaging scans, and either Floatation-REST or documentary viewing. Follow-up surveys will be completed virtually up to one week after final intervention session.

The primary aim is to evaluate the safety and tolerability of Floatation-REST in this population. Secondary aims will explore whether Floatation-REST is associated with acute changes in PTSS, perceived stress, anxiety, burnout, mood, mindfulness, and moral injury-related distress. Exploratory aims will examine whether changes in brain network connectivity, salivary cortisol, and blood-based proteomic markers may help explain symptom change. Results from this early-stage study will help determine whether Floatation-REST should be further studied as a potential intervention for post-traumatic stress symptoms in frontline healthcare and emergency personnel.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Work-related post-traumatic stress dysfunction as measured by either of the following inclusion pathways:

(A) PTSS Pathway: PCL-5 greater than or equal to 20, OR meets criteria for full or partial PTSD on the MINI International Neuropsychiatric Interview 7 (DSM-V) (Criteria A + at least 2 B-E Criteria) OR (B) Functionally Anchored Pathway: evidence of work-related trauma exposure on the MINI International Neuropsychiatric Interview 7 (DSM-V) (Criterion A) or Life Events Checklist-5, and at least one of the following: Moral Injury and Distress Scale greater than or equal to 27, Sheehan Disability Scale greater than or equal to 5 on at least 1 of the 3 subscales, high or very high level of perceived stress (measured by PhenX Perceived Stress Scale greater than or equal to 16).

  • First responder or other emergency medical personnel
  • Ability to read, speak and understand English
  • Capable of providing consent

Exclusion criteria

  • History of neurological conditions
  • Skin conditions or open wounds
  • DSM-5 diagnosis of psychotic spectrum disorders, obsessive-compulsive disorder, bipolar disorder, severe substance use disorder, or eating disorder
  • Inability to lay comfortably in a shallow pool of water
  • Failure to adhere to "pre-float checklist"
  • Breathalyzer test positive for alcohol or a drug-positive urine test
  • Unwillingness to provide consent or complete major aspects of protocol
  • MRI contraindications
  • Unstable medical diagnoses
  • Pregnancy
  • Evidence of inability to comply with study procedures based on experimenter judgement
  • Change in the dose or prescription of a medication within the 6 weeks before enrolling in the study that could affect brain functioning (e.g., anxiolytics, antipsychotics, antidepressants, benzodiazepines, or mood stabilizers)

Treatment and study plan

Floatation-REST

Behavioral

Participants float supine in a shallow pool of water saturated with Epsom salt. The environment is designed to minimize external stimulation via multiple channels including sound, light, and temperature.

Documentary

Behavioral

Participants will sit in a quiet room and watch a documentary.

Primary outcomes

  1. Adverse effects

    Time frame: From baseline to post-intervention seven day follow-up

    Safety will be assessed using adverse events reported directly to study staff and adverse effects reported on the Floatation-REST effects checklist after each Floatation-REST or comparator session. As a proxy of safety, adverse effects will be calculated for each participant as the number of instances during the study in which the participant reports an increase above mild for any negatively experienced effect on the checklist.

  2. Dropout Rate

    Time frame: Baseline through seven day post-intervention follow up

    As a proxy for tolerability, dropout rate for each arm = (# of subjects who are withdrawn from the study)/(# participants in specific arm).

Secondary outcomes

  1. Burnout Effects of Floatation-REST

    Time frame: Baseline through seven day post-intervention follow up

    Burnout measured using the MBI-HSS questionnaire after each experimental session and at follow-up time points

  2. Perceived Stress Effects of Floatation-REST

    Time frame: Baseline through seven day post-intervention follow up

    Perceived stress measured using the Perceived Stress Scale after each experimental session and at follow-up time points

  3. Moral Injury Effects of Floatation-REST

    Time frame: Baseline through seven day post-intervention follow up

    Moral injury measured using the Moral Injury and Distress Scale after each experimental session and at follow-up time points

  4. Depressive Symptomatology Effects of Floatation-REST

    Time frame: Baseline through seven day post-intervention follow up

    Depressive symptoms measured using the Quick Inventory of Depressive Symptomatology (QIDS-SR) after each experimental session and at follow-up time points

Study contacts

Contact information is provided by the study sponsor or research team.

Adrienne Taren, MD, PhD

CONTACT

[email protected]

918-340-4116

Emily M Choquette, PhD

CONTACT

[email protected]

918-240-2583

Sponsors and collaborators

Lead sponsor

Laureate Institute for Brain Research, Inc.

Other

Registry information

Official study title

Neural Mechanisms of Floatation-REST Therapy for Post-Traumatic Stress Symptoms in Frontline Healthcare Workers

Acronym: PTSS FLOAT

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
Jul 17, 2026
Registry last updated
Jul 17, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.